Why Are People Talking About Investing in REGN?

By Blake Campbell • Thursday, May 04 12:05 • Permanent Link

One of the losers of today's trading session was Regeneron Pharmaceuticals. Shares of the Pharmaceutical company plunged -6.4%, and some investors may be wondering if its price of $751.44 would make a good entry point. Here's what you should know if you are considering this investment:

Regeneron Pharmaceuticals has moved 25.6% over the last year, and the S&P 500 logged a change of -1.4%
REGN has an average analyst rating of buy and is -15.35% away from its mean target price of $887.7 per share
Its trailing earnings per share (EPS) is $38.07
Regeneron Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of 19.7 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $44.63 and its forward P/E ratio is 16.8
The company has a Price to Book (P/B) ratio of 3.55 in contrast to the S&P 500's average ratio of 2.95
Regeneron Pharmaceuticals is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
REGN has reported YOY quarterly earnings growth of -46.7% and gross profit margins of 0.6%
The company has a free cash flow of $2.64 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.